Pacific Biomarkers announces the expansion of its services portfolio to include ultra-sensitive biomarker assays using the Singulex Erenna Immunoasay technology.
Pacific Biomarkers will now provide enhanced clinical laboratory services to researchers analyzing biomarkers using the Cira platform.
Pacific Biomarkers uses an Lp(a) method that gives mass
values for different Lp(a) variants that are essentially
identical to the Marcovina method.
The Pacific Biomarkers-Clinigene partnership combines biomarker support for clinical trial research of the former with development capabilities of ligandbinding assays of the latter in a cost-effective business model situated in India.